|
1）Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimerʼs disease with Pittsburgh Compound-B. Ann Neurol. 2004; 55: 306-19
|
|
|
|
2）Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010; 51: 913-20
|
|
|
|
|
|
3）Vandenberghe R, Van Laere K, Ivanoiu A, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010; 68: 319-29
|
|
|
|
|
|
4）Kikuchi A1, Takeda A, Okamura N, et al. In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro) ethoxy]benzoxazole positron emission tomography in multiple system atrophy. Brain. 2010; 133(Pt 6): 1772-8
|
|
|
|
|
|
5）Shoghi-Jadid K, Small GW, Agdeppa ED, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry. 2002; 10: 24-35
|
|
|
|
|
|
6）Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013; 79: 1094-108
|
|
|
|
|
|
7）Okamura N, Furumoto S, Harada R, et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med. 2013; 54: 1420-7
|
|
|
|
|
|
8）Okamura N, Furumoto S, Fodero-Tavoletti MT, et al. Non-invasive assessment of Alzheimerʼs disease neurofibrillary pathology using 18F-THK5105 PET. Brain. 2014; 137(Pt 6): 1762-71
|
|
|
|
|
|
9）Chien DT, Bahri S, Szardenings AK, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013; 34: 457-68
|
|
|
|
|
|
10）Chien DT, Szardenings AK, Bahri S, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis. 2014; 38: 171-84
|
|
|
|
|
|
11）Fodero-Tavoletti MT, Furumoto S, Taylor L, et al. Assessing THK523 selectivity for tau deposits in Alzheimerʼs disease and non-Alzheimerʼs disease tauopathies. Alzheimers Res Ther. 2014; 6: 11
|
|
|
|
|
|
12）Karran E, Hardy J. Antiamyloid therapy for Alzheimerʼs disease--are we on the right road? N Engl J Med. 2014; 370: 377-8
|
|
|
|
|
|
13）Giacobini E, Gold G. Alzheimer disease therapy--moving from amyloid-β to tau. Nat Rev Neurol. 2013; 9: 677-86
|
|
|
|
|
|
14）Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Aβ42 immunisation in Alzheimerʼs disease: follow-up of a randomised, placebo-controlled phase I trial. The Lancet. 2008; 372: 216-23
|
|
|
|
|
|
15）Arriagada PV, Growdon JH, Hedley-Whyte ET, et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimerʼs disease. Neurology. 1992; 42(3 Pt 1): 631-9
|
|
|
|
|
|
16）Lewis J1, Dickson DW, Lin WL, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001; 293: 1487-91
|
|
|
|
|
|
17）Stein TD, Alvarez VE, McKee AC. Chronic traumatic encephalopathy: a spectrum of neuropathological changes following repetitive brain trauma in athletes and military personnel. Alzheimers Res Ther. 2014; 6: 4
|
|
|
|
|
|
18）Gandy S, Ikonomovic MD, Mitsis E, et al. Chronic traumatic encephalopathy: clinical-biomarker correlations and current concepts in pathogenesis. Mol Neurodegener. 2014; 9: 37
|
|
|
|
|
|
19）Mitsis EM, Riggio S, Kostakoglu L, et al. Tauopathy PET and amyloid PET in the diagnosis of chronic traumatic encephalopathies: studies of a retired NFL player and of a man with FTD and a severe head injury. Transl Psychiatry. 2014; 4: e441
|
|
|
|
|
|
20）Braak H, Del Tredici K. The pathological process underlying Alzheimerʼs disease in individuals under thirty. Acta Neuropathol. 2011; 121: 171-81
|
|
|
|
|